Role of central endpoint adjudication and challenges in trials on neonatal sepsis—a case of ProSPoNS trial
Author:
Sinha Anju PradhanORCID, Raja Dilip, Mahajan Kamlesh S., Sharma Piyu, Gupta Subodh S., Poluru Ramesh, Kawade Anand S., Dayma Girish, Sazawal Sunil, Bavdekar Ashish, Parida Sailajanandan, Nangia Sushma, Raut Abhishek V., Bethou Adhisivam, Devi Prabhabati, Gorpade Makrand, Fatima Tharika, Nayak Rashmita, Kapil Arti, Azam Mohd., Khan Pearlin A., Pandey Ravindra Mohan, Arora Narendra Kumar, Prajapati Dixit, Mathur Apoorva, Gupta Pankaj, Kumari Payal,
Abstract
AbstractDespite progress in reducing the infant mortality in India, the neonatal mortality decline has been slower, necessitating concerted efforts to achieve Sustainable Development Goal-3. A promising strategy aiming to prevent neonatal sepsis in high-risk, vulnerable, low birth weight neonates through an innovative intervention includes probiotic supplementation. This article communicates the decision by the ProSPoNS trial investigators to establish a Central Endpoint Adjudication Committee (CEAC) as an addendum to the protocol published in Trials in 2021 for the purpose of clarifying the primary outcome. In the published protocol, the study hypothesis and primary objective are based on “sepsis,” the primary outcome has been specified as sepsis/PSBI, whereas the sample size estimation was performed based on the “physician diagnosed sepsis.” To align all the three above, the investigators meeting, held on 17th–18th August 2023, at MGIMS Sevagram, Wardha, deliberated and unanimously agreed that “physician diagnosed sepsis” is the primary study outcome which includes sepsis/PSBI. The CEAC, chaired by an external subject expert and members including trial statistician, a microbiologist, and all site principal investigators will employ four criteria to determine “physician diagnosed sepsis”: (1) blood culture status, (2) sepsis screen status, (3) PSBI/non-PSBI signs and symptoms, and (4) the clinical course for each sickness event. Importantly, this clarification maintains consistency with the approved study protocol (Protocol No. 5/7/915/2012 version 3.1 dated 14 Feb 2020), emphasizing the commitment to methodological transparency and adherence to predefined standards. The decision to utilize the guidance of a CEAC is recommended as the gold standard in multicentric complex clinical trials to achieve consistency and accuracy in assessment of outcomes.Trial registrationClinical Trial Registry of India (CTRI) CTRI/2019/05/019197. Registered on 16 May 2019.
Funder
Indian Council of Medical Research
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Sinha AP, Gupta SS, Poluru R, Raut A V., Arora NK, Pandey RM, et al. Evaluating the efficacy of a multistrain probiotic supplementation for prevention of neonatal sepsis in 0–2-month-old low birth weight infants in India-the ‘ProSPoNS’ Study protocol for a phase III, multicentric, randomized, double-blind, placebo-controlled trial. Trials. 2021 [cited 2023 Dec 6];22. Available from: https://pubmed.ncbi.nlm.nih.gov/33794969/. 2. Sinha A, Gupta SS, Chellani H, Maliye C, Kumari V, Arya S, et al. Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial. BMJ Open. 2015;5:e006564. Available from: https://bmjopen.bmj.com/content/5/7/e006564. 3. World Health Organization, United Nations Children’s Fund (UNICEF). Managing possible serious bacterial infection in young infants 0–59 days old when referral is not feasible: WHO/UNICEF joint statement. 2017. Available from: https://apps.who.int/iris/handle/10665/254502. 4. GtR. [cited 2024 Jan 18]. Available from: https://gtr.ukri.org/projects?ref=MR%2FS004912%2F1. 5. Ministry of Health & Family Welfare, Government of India. In service integrated management of neonatal and childhood management (module 1 to module 9). Government of India New Delhi; 2009. Available at: Accessed:https://nhm.gov.in/images/pdf/programmes/child-health/guidelines/module_1.pdf.
|
|